menu
    • menu
    [{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Nephrology","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Nephrology","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Nephrology","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Nephrology","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"JTT-851","moa":"Free fatty acid receptor 1 (GPR40)","graph1":"Endocrinology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JTK-853","moa":"Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JTK-853","moa":"Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JTK-853","moa":"Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"JTE-451","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"JTE-451","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"JTT-251","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"JTT-251","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JTT-861","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akros Pharma \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Icon Plc"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"JTE-051","moa":"T-cell-specific kinase (ITK)","graph1":"Immunology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"JTE-051","moa":"T-cell-specific kinase (ITK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"JTT-252","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JTT-662","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akros Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Akros Pharma

    Menu

    Akros Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTT-861

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fra...

                            Details : JTT-861 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 30, 2023

                            Lead Product(s) : JTT-861

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTT-662

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2...

                            Details : JTT-662 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 10, 2020

                            Lead Product(s) : JTT-662

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTE-451

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

                            Details : JTE-451 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 06, 2019

                            Lead Product(s) : JTE-451

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTT-251

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

                            Details : JTT-251 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2018

                            Lead Product(s) : JTT-251

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTE-051

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

                            Details : JTE-051 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 30, 2017

                            Lead Product(s) : JTE-051

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTE-451

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasi...

                            Details : JTE-451 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 12, 2017

                            Lead Product(s) : JTE-451

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTE-051

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

                            Details : JTE-051 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 29, 2016

                            Lead Product(s) : JTE-051

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enarodustat

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

                            Details : JTZ-951 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2016

                            Lead Product(s) : Enarodustat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enarodustat

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

                            Details : JTZ-951 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2015

                            Lead Product(s) : Enarodustat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Akros Pharma

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTT-252

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

                            Details : JTT-252 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 23, 2014

                            Lead Product(s) : JTT-252

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth